Sign in

You're signed outSign in or to get full access.

DI

DATASEA INC. (DTSS)·Q4 2023 Earnings Summary

Executive Summary

  • FY 2023 revenue was $7.05M (-59% YoY), gross profit $0.34M, and net loss widened to $9.48M (EPS $(0.38) vs $(0.27) in FY 2022), reflecting COVID disruptions and strategic restructuring away from low-margin 5G SMS volumes .
  • Quarterly detail for Q4 FY2023 (three months ended June 30, 2023) was not itemized in the company’s release; the firm reported annual results and qualitative commentary, while Q2 and Q3 quarterly data show revenue of $0.43M and $1.79M, respectively, with gross margin compression into Q3 .
  • 5G messaging remained the core revenue driver in FY 2023 ($6.69M), led by Top-up services ($4.48M), with management citing a consumption recovery that accelerated Top-up growth in Q4 FY2023 .
  • Strategic pivot toward Intelligent Acoustics continued (U.S. subsidiary Datasea Acoustics LLC established July 31, 2023) as a platform for antiviral ultrasonic products; no formal numeric guidance was issued for Q4, and no earnings call transcript was filed .
  • Potential stock reaction catalysts: reported acceleration in 5G Top-up in Q4, internationalization via U.S. subsidiary, and continued product pipeline in acoustic health/sleep—offset by liquidity constraints and persistent losses highlighted in filings .

What Went Well and What Went Wrong

What Went Well

  • “Internationalization has always been a crucial strategy… Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, USA” to launch antiviral ultrasonic solutions and new products (e.g., ultrasonic Skin Repair Robot) .
  • 5G Top-up business saw “rapid growth in the fourth quarter of 2023” as consumption recovered following policy changes; FY 2023 5G messaging net revenue reached $6.69M, with $4.48M from Top-up .
  • Management underscored acoustic technology leadership and industry recognition, including the inaugural white paper on acoustic intelligence and collaborations with leading labs (e.g., Wuhan Institute of Virology efficacy data) .

What Went Wrong

  • FY 2023 revenue fell 59% to $7.05M, driven by reduced 5G SMS demand amid COVID and strategy changes; net loss expanded to $9.48M and operating loss to $9.69M .
  • Gross profit fell to $0.34M, while operating expenses increased to $10.03M (G&A up to $8.41M), reflecting investment and cost structure amid declining volumes .
  • Liquidity constraints and going-concern commentary; working capital deficits and Nasdaq compliance issues highlighted across 10-Q/10-K, despite subsequent equity financings .

Financial Results

Quarterly performance (oldest → newest)

MetricQ2 FY2023 (3M ended Dec 31, 2022)Q3 FY2023 (3M ended Mar 31, 2023)Q4 FY2023 (3M ended Jun 30, 2023)
Revenue ($USD)$425,710 $1,787,677
EPS ($USD)$(0.05) $(0.05)
Gross Margin (%)12.8% 5.4%

Note: The company did not itemize Q4 FY2023 revenue/EPS in its 8-K FY results; only annual data was disclosed .

FY results (YoY)

MetricFY 2022FY 2023
Revenue ($USD)$17,080,911 $7,045,311
Gross Profit ($USD)$955,673 $340,931
Operating Expenses ($USD)$8,192,927 $10,026,151
Operating Loss ($USD)$(7,237,254) $(9,685,220)
Net Loss ($USD)$(6,521,708) $(9,479,692)
Diluted EPS ($USD)$(0.27) $(0.38)
Weighted Avg Shares23,956,393 24,951,868

Segment/KPI highlights

KPI / SegmentFY 2023
5G Messaging Net Revenue ($USD)$6,686,691
Of which: 5G Top-up ($USD)$4,481,442
Acoustic Intelligence Net Revenue ($USD)$136,884
Accounts Receivable ($USD, Jun 30, 2023)$255,725
Cash ($USD, Jun 30, 2023)$19,728
Total Liabilities ($USD, Jun 30, 2023)$6,334,545

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ4 FY2023Not providedNot providedMaintained (no formal guidance)
MarginsQ4 FY2023Not providedNot providedMaintained (no formal guidance)
OpExQ4 FY2023Not providedNot providedMaintained (no formal guidance)
Tax RateQ4 FY2023Not providedNot providedMaintained (no formal guidance)
Segment-specificQ4 FY2023Not providedNot providedMaintained (no formal guidance)
DividendsQ4 FY2023NoneNoneMaintained (no dividends)

Earnings Call Themes & Trends

Note: No Q4 FY2023 earnings call transcript was found; themes are drawn from the FY 2023 press release and Q2/Q3 filings.

TopicPrevious Mentions (Q2 FY2023)Previous Mentions (Q3 FY2023)Current Period (Q4 FY2023)Trend
5G Messaging demand/Top-upCOVID policy changes drove sharp declines; revised policy to prepay to mitigate risk Platform upgrades; new recharge cooperation; multi-operator expansion Consumption recovery “rapidly” grew Top-up in Q4 FY2023; 5G messaging $6.69M FY Improving sequentially in Q4
Intelligent Acoustics strategyHailijia campaign; eight distribution agreements; initial sales Continued product development (bathroom deodorization, sleep, non-contact beauty) CEO reaffirms acoustics as core; U.S. subsidiary to drive global markets Sustained strategic emphasis
International expansionN/APreparing export/overseas expansion; product certifications planned Datasea Acoustics LLC established in Delaware (July 31, 2023) Accelerating
Liquidity/NasdaqN/ANasdaq MVLS deficiency letter; working capital deficit Subsequent equity offerings/subscriptions in Aug–Sep 2023 Addressing constraints
ESGESG framework adoption planned; report forthcoming Quarterly ESG report aligned to SASB published; ongoing updates Continued emphasis in filings Incremental progress

Management Commentary

  • CEO perspective on strategy: “Internationalization has always been a crucial strategy for us… We will introduce cutting-edge antiviral acoustic solutions to the U.S. market… and launch new products such as ultrasonic Skin Repair Robot…” — Zhixin Liu, CEO .
  • Acoustic intelligence priority: “A more important measure of our success than short-term revenue is the establishment of Acoustic Intelligence as the core of our company’s strategy… ultrasound, Schumann resonance technology and directional sound” — Zhixin Liu, CEO .
  • Business drivers and restructuring: Management cited COVID disruptions, supply chain impacts, and strategic restructuring away from low-margin lines as drivers of lower FY revenue .

Q&A Highlights

  • No earnings call transcript was filed for Q4 FY2023; therefore, no formal Q&A highlights or guidance clarifications are available [functions.ListDocuments returned none for “earnings-call-transcript”].

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 FY2023 EPS/revenue was unavailable via the estimates tool due to request limits; the company provided no formal guidance in the FY press release .
  • With no consensus available, estimate comparisons cannot be made; investors should anchor on reported FY and interim (Q2/Q3) actuals .

Key Takeaways for Investors

  • Sequential recovery in 5G Top-up likely supported Q4 FY2023 activity, but absent quarterly disclosure, reliance is on annual and Q2/Q3 data; watch for explicit quarterly detail in subsequent filings .
  • Strategic pivot to Intelligent Acoustics continues, with U.S. entry (Datasea Acoustics LLC) as a potential medium-term growth vector across antiviral, cosmetic, and sleep products; near-term revenue scale remains modest ($0.14M acoustic revenue in FY2023) .
  • Persistent losses and elevated OpEx against declining annual revenue underscore execution and cost-discipline risk; liquidity remains a central focus despite subsequent financings .
  • Margin trajectory deteriorated into Q3 (5.4% gross margin) given mix and scale; watch product mix shifts (higher-margin SaaS/services vs Top-up) to stabilize margins .
  • Regulatory and listing risks (Nasdaq MVLS compliance) and China-operating structure (VIE, cybersecurity/data rules) are ongoing overhangs; monitor compliance updates and CSRC filing regime developments .
  • Near-term trading: headlines around U.S. market entry, lab efficacy data, and Top-up agreements can produce upside catalysts; downside stems from lack of quarterly granularity, continued losses, and financing needs .
  • Medium-term thesis: if acoustics product commercialization scales and 5G messaging transitions to higher-value platforms, revenue mix can improve; track segment disclosure, U.S. commercialization milestones, and gross margin recovery .